MEDIPOST Co (078160) Fair Value & Analysis
Healthcare · KR · Market cap 412B KRW
Fair value as of: Jun 25, 2026
Analysis
MEDIPOST Co (078160) currently trades at 8,940 KRW, while our model-based Fair Value estimate is 3,621 KRW — implying the stock looks roughly 59.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is in completed Phase II clinical trial in South Korea, as well as in Phase I/II clinical trial in the United States for the preventative treatment of bronchopulmonary dysplasia; and NEUROSTEM that is in Phase I/IIa clinical study to treat Alzheimer's disease. Further, the company develops SMUP-IA-01, which has completed phase I clinical trial for the treatment of osteoarthritis; and SMUP-IV-01 for the treatment of diabetic nephropathy, as well as offers nutritional and dietary supplements under the MOVITA brand nam…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is MEDIPOST Co (078160) undervalued?
What is the fair value of 078160?
What is the quality score of 078160?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.